Rex Bionics investors have backed a deal that will see their investment diluted to little more than a third of the company in exchange for a A$10 million (NZ$10.7m) lifeline by Australian fund manager and fellow shareholder BioScience Managers.
TOP
©copyright Medical Technology Association of New Zealand, all rights reserved. Privacy Policy and Disclaimer.